WEIFANG, Shandong, China, Aug. 11
/PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical (OTC
Bulletin Board: SGTI), announced today that it has retained DME
Capital LLC, a New York-based
Investor Relations firm, to expand the Company's strategic investor
relations program.
Mr. Qingtai Liu CEO of Shengtai Pharmaceutical stated, "As we
continue to grow our operations, we believe this is the right time
to send our message to the investment community. After careful
consideration, DME Capital, with their established relationships
among institutional investors, combined with their extensive
databases and pro active investor relations program, is the perfect
partner for Shengtai Pharmaceutical."
About DME Capital LLC
DME Capital LLC is a full service investor relations firm,
representing growth oriented companies to the investment community.
Investor Relations services include financial community and media
relations, editorial services and interactive communications, as
well as administrative, consulting and advisory services. DME
Capital LLC ensures money, fund, and portfolio managers, financial
analysts, brokers and individual investors receive a constant flow
of information and updates. To learn more about DME Capital LLC go
to http://www.dmecapital.com .
About Shengtai Pharmaceutical:
Shengtai Pharmaceutical founded in 1999 is a leading domestic
producer of pharmaceutical-grade glucose in China. The company has about 40% of the market
and one of the only three licensed Dextrose Monohydrate
manufacturers in China. With
increased production capacity ready, the company will have
potential to acquire 50% of China's pharmaceutical glucose market in about
1-2 years. The Company has had great growth revenue in the past
several years. The company's products include pharmaceutical-grade
glucose or dextrose, used for medical purposes as well as other
glucose and cornstarch products used for the food and beverage
industry, and for industrial productions in China. The company's main customers include
medical supply companies, pharmaceutical companies, medical supply
exporters, and food and beverage companies covering all of
China with the exception of Tibet.
The Company also exports its products to more than 70 different
countries.
Safe Harbor: This letter contains certain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended and Section 21E of the Securities Exchange Act
of 1934, as amended, which are intended to be covered by the safe
harbors created thereby. Investors are cautioned that all
forward-looking statements involve risks and uncertainty, including
without limitation, the ability of the Company to successfully
implement its turnaround strategy, changes in costs of raw
materials, labor, and employee benefits, as well as general market
conditions, competition and pricing. Although the Company believes
that the assumptions underlying the forward-looking statements
contained herein are reasonable, any of the assumptions could be
inaccurate, and therefore, there can be no assurance that the
forward-looking statements included in this letter will prove to be
accurate. In light of the significant uncertainties inherent in the
forward-looking statements included herein, the inclusion of such
information should not be regarded as representation by the Company
or any other person that the objectives and plans of the Company
will be achieved. In assessing forward-looking statements included
herein, readers are urged to carefully read those statements. When
used in the Annual Report on Form 10-K, the words "estimate,"
"anticipate," "expect," "believe," and similar expressions are
intended to be forward-looking statements.
For more information, please contact:
Shengtai Pharmaceutical, Inc.
Tel: +86-536-629-5802
Email: shengtaigsz@hotmail.com
Investor Relations:
DME Capital LLC
Steven Marcus
Tel: +1-917-648-0663
SOURCE Shengtai Pharmaceutical, Inc.
Copyright . 11 PR Newswire